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Clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated protein (Cas) technology has 
emerged as a programmable RNA-guided DNA-targeting 
tool for sequence-specific genome editing in diverse organ-
isms. The most frequently used CRISPR/Cas system, which 
is based on the bacterium Streptococcus pyogenes Cas9 
(SpCas9) endonuclease, has been repurposed into a suite of 
versatile tools for numerous DNA-manipulating activities 
beyond genome editing (Jiang and Marraffini, 2015). How-
ever, progress in converting the CRISPR/SpCas9 system 
into a sequence-specific RNA-manipulating platform has 
been limited. A recent study published in Science by 
Abudayyeh and colleagues (Abudayyeh et al., 2016) has 
identified Leptotrichia shahii C2c2 (LshC2c2) to be a novel 
programmable RNA-targeting endoribonuclease with great 
potential to reshape the landscape of future RNA research. 
Current CRISPR/SpCas9 technology was originally de-
veloped from the bacterial type-II CRISPR/Cas adaptive 
immune system, which evolves to purge invading bacterio-
phage and plasmid DNA. In this technology, a single syn-
thetic guide RNA (sgRNA) containing a 20-nt guide (also 
known as spacer) sequence is used to target the SpCas9 nu-
clease to an intended genomic N20NGG (N for any base) 
sequence through RNA-DNA base pairing (Figure 1A). 
“NGG” is known as the protospacer adjacent motif (PAM), 
which is absolutely required for SpCas9 target recognition. 
Subsequent DNA cleavage by SpCas9 generates a DNA 
double-strand break, which in turn leads to target gene mu-
tagenesis or replacement as a result of DNA repair. As the 
DNA-targeting specificity is determined by RNA-DNA 
complementarity, the CRISPR/SpCas9 system exhibits un-
precedented simplicity and multiplexability compared to 
earlier genome editing tools (e.g., zinc-finger nucleases 
(ZFNs) and transcription-activator like effector nucleases 
(TALENs)) that are based on protein-DNA interaction. 
These striking merits have also stimulated the conversion of 
nuclease-dead SpCas9 (dCas9) into a programmable 
DNA-binding platform. When fused with different effector 
domains (e.g., a fluorescent protein or transcriptional or 
epigenetic regulatory domains), the dCas9-effector chimera 
empowers specific labeling or regulatory activities at spe-
cific DNA sequences in a genome (Dominguez et al., 2016). 
RNA plays indispensable roles within cells, as building 
blocks (e.g., mRNA, tRNA, and rRNA) or regulatory com-
ponents (e.g., miRNA and lncRNA) of gene transcription 
and protein translation machineries, as well as genetic in-
formation carriers (i.e., viral RNA). Therefore, it is highly 
desirable to control the activities of RNA molecules in a 
sequence-specific manner. A common strategy for targeted 
RNA manipulation involves engineering of RNA-binding 
proteins (e.g., PUF proteins) that have well-defined RNA- 
recognition modules but unsatisfactory RNA-targeting 
specificities (Nelles et al., 2015). The ease of the CRISPR/ 
SpCas9 system in manipulating DNA has also motivated its 
modification for RNA manipulation (O’Connell et al., 
2014). Cleavage of single-strand RNA (ssRNA) by the 
CRISPR/SpCas9 system was achieved in vitro when a 
PAM-containing oligonucleotide, termed a PAMmer, was 
supplied to complement the target ssRNA (Figure 1B). Fur-
thermore, a chimera dCas9-fluorescent protein was suc-
 Zhang, D., et al.   Sci China Life Sci   August (2016) Vol.59 No.8 855 
 
Figure 1  CRISPR/Cas systems for DNA or RNA targeting. A, Diagram of the SpCas9-sgRNA complex targeting double-strand DNA (dsDNA). PAM, 
protospacer adjacent motif. B, Diagram of the SpCas9-sgRNA complex targeting ssRNA in the presence of a PAMmer. Note that this system is also known 
as the RCas9 system. C, Diagram of the LshC2c2-crRNA complex targeting ssRNA. 
cessfully implemented to image the trafficking of specific 
mRNAs in human cells with the assistance of PAMmers 
(Nelles et al., 2016). However, for this so-called RNA-  
targeted Cas9 (RCas9) system, efficient delivery of 
PAMmers into whole animals or plants to facilitate RNA 
targeting remains a gigantic roadblock. Interestingly, the 
bacterium Francisella novicida Cas9 (FnCas9), an ortholog 
of SpCas9, was also found to associate with mRNA in bac-
teria (Sampson et al., 2013) and with viral RNA in human 
cells (Price et al., 2015). However, this system is unable to 
distinguish RNA from DNA targets. 
The work by Abudayyeh and colleagues now shows that 
the CRISPR/LshC2c2 system, which is developed from the 
type-VI CRISPR/Cas adaptive immune system in L. shahii, 
can be engineered into a programmable RNA-guided 
RNA-targeting system (Figure 1C), thus opening up a new 
avenue for RNA targeting. The authors were attracted to 
LshC2c2 because, as the only effector in this CRISPR/Cas 
system, it shows no homology to DNA nucleases, but in-
stead possesses two Higher Eukaryotes and Prokaryotes 
Nucleotide-binding (HEPN) domains, which exist in many 
RNases. Indeed, co-expression of LshC2c2 and a CRISPR 
RNA (crRNA) containing a 28-nt spacer targeting MS2 
phage RNA could confer viral resistance to E. coli. Detailed 
characterization of purified LshC2c2 in vitro showed that 
LshC2c2 only cleaves ssRNA, but not any other form of 
nucleic acid, upon recognizing an N28H (H for A, C, and U) 
target sequence complementary to the crRNA spacer. The 
authors further demonstrated that LshC2c2 cleaves exposed 
regions (e.g., loop regions) within ssRNA outside the target 
sequence, with a high preference for U residues. The HEPN 
domains of LshC2c2 appear to be responsible for RNA 
cleavage, because mutation of a putative catalytic residue 
within either HEPN domain eliminates RNA cleavage ac-
tivity. The authors next demonstrated that the spacer length 
of an effective crRNA should be at least 22 nt, and that the 
stem-loop structure of the crRNA is critical for target RNA 
recognition. Using a 28-nt spacer, the authors investigated 
the RNA-targeting specificity of LshC2c2 both in vitro and 
in E. coli, concluding that single mismatches across the 
spacer can be tolerated but two mismatches distributed in 
the central region of the spacer can dramatically compro-
mise target RNA cleavage. Finally, the authors successfully 
applied the CRISPR/LshC2c2 system to cleave target 
mRNA in E. coli. Notably, they observed remarkable 
growth arrest of E. coli, correlated with efficient knock-
down of the target mRNA. They provided evidence that the 
LshC2c2-crRNA complex, once activated by target ssRNA, 
could cleave other ssRNA non-specifically, which may lead 
to cytotoxicity and subsequent growth inhibition. 
The aforementioned study was carried out exclusively in 
E. coli and in vitro. It would be compelling to test whether 
this system could effectively cleave ssRNA in eukaryotic 
cells. It might be possible that the cytotoxicity of tar-
get-activated LshC2c2 is limited to E. coli, as the cytotoxi-
city of SpCas9 has only been witnessed in single-cell or-
ganisms, such as E. coli, Agrobacterium, and Chlamydo-
monas, but never in mammalian or plant cells. If this were 
not true, application of the CRISPR/LshC2c2 system for 
degrading target mRNA or other non-coding RNA would be 
problematic. We hope that comparison of the crystal struc-
tures of target-activated and idling LshC2c2-crRNA com-
plexes will offer guidance for creating an improved variant 
of LshC2c2 with tightly controllable cleavage activity. 
Transformation of the CRISPR/LshC2c2 system into a 
weapon against RNA viruses causing human and plant dis-
eases (Zhang et al., 2015) represents another attractive pos-
sibility. When comparing the CRISPR/LshC2c2 system to 
current gene silencing or antiviral technologies, such as 
RNAi and artificial miRNA (amiRNA), it is still too early to 
determine whether the former will render the latter obsolete. 
For instance, the minimal spacer length (≥22 nt) required 
by LshC2c2 limits its utility for cleaving small non-coding 
RNA (e.g., 21-nt miRNA), which can be destroyed using 
complimentary amiRNA. 
Compared to wild type, ribonuclease-dead dC2c2 may be 
more valuable as a programmable sequence-specific RNA- 
binding platform, assuming that the target RNA-dC2c2 as-
sociation is frozen without cleavage to promote the release 
of target RNA substrate and re-binding of another non-  
target RNA. It is conceivable that dC2c2 could be useful in 
the following applications: (i) visualization of localization 
and trafficking of a specific mRNA in a cell or labeling 
specific cells expressing a certain mRNA via fluorescently 
tagged dC2c2, (ii) sequestration of a specific mRNA at a 
desired subcellular locus via co-localization with dC2c2, 
(iii) boosting protein production from a specific mRNA, 
using a dC2c2 fusion with an RNA-stabilizing protein or 
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translation-enhancing factor, (iv) alteration of the splicing 
pattern of a specific mRNA by fusion of dC2c2 with a 
splicing factor, (v) C-to-U editing of a specific mRNA using 
a dC2c2-cytidine deaminase chimera, (vi) pulling down a 
specific RNA to identify its associated proteins, and (vii) 
evaluating the interaction between a candidate protein and a 
specific RNA by BiFC with dC2c2 and the candidate pro-
tein fused respectively to split fluorescent proteins. It is 
noteworthy that effector domains can also be recruited as a 
fusion to the MS2 coat protein (MCP) through a 
MCP-binding aptamer embedded within the stem-loop re-
gion of crRNA, as long as aptamer insertion does not impair 
the stem-loop structure. As Abudayyeh et al. noted, the 
secondary structure of the target RNA can greatly affect the 
targeting efficiency of the LshC2c2-crRNA complex 
(Abudayyeh et al., 2016), presumably owing to the variable 
accessibility of different target sequences within a compli-
catedly folded ssRNA. Therefore, it is most desirable to 
screen multiple target sequences from the same target RNA 
to identify the most effective one for a given application. 
The elegance of LshC2c2/dC2c2 performance in vivo 
will ultimately rely on its targeting specificity, which awaits 
systematic validation and has room for improvement. One 
strategy for specificity improvement is to reduce the length 
of the crRNA spacer from 28 nt to an optimal length that 
allows sufficient affinity between crRNA and the target 
RNA while substantially increasing the sensitivity of the 
system to mismatches within the crRNA-ssRNA duplex. A 
truncated sgRNA strategy has been adopted to reduce 
off-target effects in the CRISPR/SpCas9 system (Fu et al., 
2014). One caveat is that the crRNA-ssRNA duplex may 
induce the synthesis of double-strand RNA within eukary-
otic cells, which could in turn trigger secondary RNAi 
events, leading to unwanted off-target silencing. Shortening 
the spacer length of the crRNA could help minimize this 
possibility. Another strategy to improve the targeting speci-
ficity of LshC2c2/dC2c2 is based on structural insights. For 
example, structure-guided engineering has been applied to 
generate an enhanced SpCas9 that exhibits extremely high  
DNA-targeting specificity (Slaymaker et al., 2016). Identi-
fication of a new bacterial antiviral RNase analogous to  
LshC2c2 with better targeting specificity and little or no 
promiscuous cleavage activity is also a possibility. Consid- 
ering the incredible pace of development of CRISPR tech-
nology, from the CRISPR/SpCas9 system to the RCas9 
system to the CRISPR/LshC2c2 system (Figure 1), the next 
significant advance in programmable RNA targeting should 
be on the horizon, which will benefit all RNA-related re-
search in biology and medicine. 
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